July Knowledge Translation Update

Coming Soon – Series of Webinars on Knowledge Translation

Knowledge translation (KT) is a dynamic and iterative process that includes dissemination of knowledge to provide more effective health services and products, and to strengthen the health care system [1]. KT products (e.g., leaflets, videos, websites) are important tools to inform health care providers, patients and families about the process of KT, thereby ensuring that they have the confidence and knowledge needed to bring their expertise forward to guide discussions and inform decisions regarding health care, research, and therapy development for Canadians living with Neuromuscular Diseases (NMD). 

The NMD4C is excited to announce the launch of a series of webinars that will support KT abilities, with the first webinar to be held on Wednesday, September 29th. 

 

Please stay tuned for more details to come!

 

Meet our Newest Team Member : Samar Muslemani

We are happy to welcome Ms. Samar Muslemani to the KT team. Samar is an occupational therapist and research student who will support the KT team and act as a knowledge broker for the NMD4C.

Samar will take over her role from Dr. Valérie Gagné; the NMD4C are very appreciative of all the hard work that Dr. Gagné has done for the network over the past year, and we would like to wish her the best in her future pursuits.

 

[1] https://cihr-irsc.gc.ca/e/29418.html

Useable_KT_updates

Read next...

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.

Website - SBMA published on CMAJ.png

New Best Practice Recommendations for SBMA Care in Canada

Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!

2025 NMD4C ANNUAL MEETING

Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting

On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.

2025 Clinical Summer School

NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders

On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.

2026 Neuromuscular Postdoc Research Fellowship Competition

2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!

Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)

Clinical Fellowship Awardees

Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients

We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.